Marna Williams

3.3k total citations · 1 hit paper
21 papers, 1.6k citations indexed

About

Marna Williams is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Infectious Diseases. According to data from OpenAlex, Marna Williams has authored 21 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Immunology and 6 papers in Infectious Diseases. Recurrent topics in Marna Williams's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Viral gastroenteritis research and epidemiology (4 papers) and CAR-T cell therapy research (4 papers). Marna Williams is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Viral gastroenteritis research and epidemiology (4 papers) and CAR-T cell therapy research (4 papers). Marna Williams collaborates with scholars based in United States, United Kingdom and Japan. Marna Williams's co-authors include Lusijah Rott, Eugene C. Butcher, Michael Briskin, Eugene C. Butcher, Kenneth R. Youngman, Harry B. Greenberg, L S Rott, Jacqueline Rose, M. Franco and Rakesh Dixit and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Marna Williams

20 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lymphocyte Trafficking and Regional Immunity

1999 543 citations Eugene C. Butcher, Marna Williams et al. Advances in immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marna Williams United States	15	897	529	271	249	244	21	1.6k
Paul von Hoegen Germany	22	971 1.1×	336 0.6×	162 0.6×	385 1.5×	160 0.7×	40	1.4k
Morris O. Dailey United States	25	1.2k 1.3×	320 0.6×	247 0.9×	431 1.7×	460 1.9×	43	1.9k
David Stephany United States	21	1.7k 1.9×	401 0.8×	400 1.5×	404 1.6×	324 1.3×	35	2.6k
Bernardetta Nardelli United States	23	1.8k 2.0×	500 0.9×	455 1.7×	671 2.7×	154 0.6×	41	2.8k
A I Lazarovits Canada	21	1.2k 1.3×	156 0.3×	289 1.1×	253 1.0×	596 2.4×	41	1.9k
L S Rott United States	13	1.4k 1.6×	240 0.5×	237 0.9×	424 1.7×	929 3.8×	14	2.3k
Marco Bestagno Italy	25	462 0.5×	552 1.0×	481 1.8×	800 3.2×	136 0.6×	51	1.9k
Eugene C. Butcher United States	7	1.0k 1.2×	269 0.5×	93 0.3×	187 0.8×	432 1.8×	9	1.4k
Juan R. de los Toyos Spain	19	410 0.5×	246 0.5×	245 0.9×	676 2.7×	434 1.8×	48	1.7k
M. Hadam Germany	24	1.2k 1.4×	413 0.8×	226 0.8×	576 2.3×	96 0.4×	66	2.0k

Countries citing papers authored by Marna Williams

Since Specialization

Citations

This map shows the geographic impact of Marna Williams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marna Williams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marna Williams more than expected).

Fields of papers citing papers by Marna Williams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marna Williams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marna Williams. The network helps show where Marna Williams may publish in the future.

Co-authorship network of co-authors of Marna Williams

This figure shows the co-authorship network connecting the top 25 collaborators of Marna Williams. A scholar is included among the top collaborators of Marna Williams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marna Williams. Marna Williams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bono, Johann S. de, Mark T. Fleming, Judy S. Wang, et al.. (2021). Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clinical Cancer Research. 27(13). 3602–3609. 33 indexed citations

Bono, Johann S. de, Mark T. Fleming, Richard Cathomas, et al.. (2020). MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.. Journal of Clinical Oncology. 38(6_suppl). 99–99. 9 indexed citations

Williams, Marna, et al.. (2020). Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions. Molecular Cancer Therapeutics. 19(9). 1770–1783. 15 indexed citations

Kumar, Shaji, Magdalini Migkou, Manisha Bhutani, et al.. (2020). Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 26–27. 51 indexed citations

Li, Dongwei, Randall Dere, Bing Zheng, et al.. (2019). Evaluation and use of an anti‐cynomolgus monkey CD79b surrogate antibody–drug conjugate to enable clinical development of polatuzumab vedotin. British Journal of Pharmacology. 176(19). 3805–3818. 23 indexed citations

Coats, Steven, Marna Williams, Rakesh Dixit, et al.. (2019). Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clinical Cancer Research. 25(18). 5441–5448. 222 indexed citations

Fuh, Franklin, Dongwei Li, Kirsten Achilles Poon, et al.. (2016). Anti‐CD22 and anti‐CD79b antibody‐drug conjugates preferentially target proliferating B cells. British Journal of Pharmacology. 174(8). 628–640. 20 indexed citations

Vermeire, Séverine, Sharon O’Byrne, Marna Williams, et al.. (2013). 159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis. Gastroenterology. 144(5). S–36. 10 indexed citations

Rutgeerts, Paul, Richard N. Fedorak, Daan W. Hommes, et al.. (2012). A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis. Gut. 62(8). 1122–1130. 111 indexed citations

10.

Emu, Brinda, Diana Luca, Jane L. Grogan, et al.. (2012). Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial. Arthritis Research & Therapy. 14(1). R6–R6. 26 indexed citations

11.

Williams, Marna, et al.. (2012). Sa2025 Etrolizumab-Mediated Ex Vivo Modulation of Beta7 Cell Surface Receptors in Nonhuman Primate and Human Peripheral Blood Supports the Proposed Mechanism of Action. Gastroenterology. 142(5). S–383.

12.

Rutgeerts, Paul, Richard N. Fedorak, Daniël W. Hommes, et al.. (2011). A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC). Gastroenterology. 140(5). S–125. 6 indexed citations

13.

Zheng, Bing, Reina N. Fuji, Kristi Elkins, et al.. (2009). In vivoeffects of targeting CD79b with antibodies and antibody-drug conjugates. Molecular Cancer Therapeutics. 8(10). 2937–2946. 42 indexed citations

14.

Hsi, Eric D., Roxanne Steinle, Balaji Balasa, et al.. (2006). CS1: A Potential New Therapeutic Target for the Treatment of Multiple Myeloma.. Blood. 108(11). 3457–3457. 4 indexed citations

15.

O’Hara, Edward, Marna Williams, Lusijah Rott, et al.. (2004). Modified representational difference analysis: isolation of differentially expressed mRNAs from rare cell populations. Analytical Biochemistry. 336(2). 221–230. 5 indexed citations

16.

Butcher, Eugene C., Marna Williams, Kenneth R. Youngman, Lusijah Rott, & Michael Briskin. (1999). Lymphocyte Trafficking and Regional Immunity. Advances in immunology. 72. 209–253. 543 indexed citations breakdown →

17.

Williams, Marna, et al.. (1998). Expression of the Mucosal Homing Receptor α₄β₇Correlates with the Ability of CD8⁺Memory T Cells To Clear Rotavirus Infection. Journal of Virology. 72(1). 726–730. 70 indexed citations

18.

Williams, Marna, Jacqueline Rose, L S Rott, et al.. (1998). The memory B cell subset responsible for the secretory IgA response and protective humoral immunity to rotavirus expresses the intestinal homing receptor, alpha4beta7.. PubMed. 161(8). 4227–35. 93 indexed citations

19.

Williams, Marna & Eugene C. Butcher. (1997). Homing of naive and memory T lymphocyte subsets to Peyer’s patches, lymph nodes, and spleen. The Journal of Immunology. 159(4). 1746–1752. 147 indexed citations

20.

Rott, L S, Jacqueline Rose, Dorsey Bass, et al.. (1997). Expression of mucosal homing receptor alpha4beta7 by circulating CD4+ cells with memory for intestinal rotavirus.. Journal of Clinical Investigation. 100(5). 1204–1208. 121 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact